MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Celsion Corp

Uždarymo kaina

0

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

25

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+1233.33% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

64K

13M

Ankstesnė atidarymo kaina

0

Ankstesnė uždarymo kaina

0

Celsion Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-04-18 14:38; UTC

Pagrindinės rinkos jėgos

Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine

Akcijų palyginimas

Kainos pokytis

Celsion Corp Prognozė

Kainos tikslas

By TipRanks

1233.33% į viršų

12 mėnesių prognozė

Vidutinis 14 USD  1233.33%

Aukščiausias 14 USD

Žemiausias 14 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celsion Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

$

Apie bendrovę Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.